Biocon gets MHRA UK nod for weight management injection Liraglutide
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-01 08:52 GMT | Update On 2024-04-01 08:52 GMT
Advertisement
Bangalore: Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.
This is further to the Company's previous intimation of 27th March, 2024, informing that approval was received fromthe MHRA for Liraglutide (gVicotza), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.